Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery.

Jean-Baptiste BonnetSarah TournayreJean AnitcheouMarion FaivreCatherine BoegnerAbdulkader JalekDominique JullienVincent AttalinJustine MyziaLucile MartyYouadigue KembaDavid Nocca Ariane Sultan Antoine Avignon

Published in: Obesity (Silver Spring, Md.) (2023)

and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.

Keyphrases

weight loss
bariatric surgery
roux en y gastric bypass
obese patients
gastric bypass
systematic review
metabolic syndrome
weight gain
type diabetes
early onset
glycemic control
risk assessment
drug induced